Hot Life Science Investor Mandate 2: European VC Interested in Wide Range of Biotech & Medtech Opportunities – March 14, 2013

12 Mar

A venture capital fund based in Denmark has over €700 million in total assets under management, and has raised three funds. The firm is currently deploying assets from its third fund, which closed in 2011. The third fund’s portfolio currently consists of four companies. They are unsure of how many transactions they will execute in 2013, but aim to have ten to twelve companies in their portfolio for their third fund, and thus would invest in a firm over the next few quarters if a compelling opportunity is identified. Their typical equity check ranges from €6-10 million.

The firm is looking for companies in the biotech therapeutics & diagnostics space, and the medtech space. The fund invests in both therapeutics & diagnostics, and will consider the full gamut of subsectors and indications within the biotech therapeutics and diagnostics, as well as in the medtech space.

The VC invests in pre-revenue, early stage companies. With that being said, they are solely looking for companies that do not currently have a product on the market. In the biotech therapeutics and diagnostics space, the firm typically prefers to invest in companies one year prior to the firm starting their phase I clinical trials. In the medtech space, the firm looks for companies that have a prototype of their device.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: